These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24355410)

  • 1. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
    Piaserico S; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Peserico A; Naldi L;
    J Am Acad Dermatol; 2014 Feb; 70(2):257-62.e3. PubMed ID: 24355410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
    Saraceno R; Pietroleonardo L; Mazzotta A; Zangrilli A; Bianchi L; Chimenti S
    Expert Opin Biol Ther; 2013 Apr; 13(4):469-73. PubMed ID: 23157654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
    Yamauchi PS; Bissonnette R; Teixeira HD; Valdecantos WC
    J Am Acad Dermatol; 2016 Sep; 75(3):612-618.e6. PubMed ID: 27061047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
    Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
    J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study.
    Jókai H; Szakonyi J; Kontár O; Marschalkó M; Szalai K; Kárpáti S; Holló P
    J Am Acad Dermatol; 2013 Oct; 69(4):523-9. PubMed ID: 23891393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
    Gilbert KE; Manalo IF; Wu JJ
    J Am Acad Dermatol; 2015 Aug; 73(2):329-31. PubMed ID: 26183982
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
    English PL; Vender R
    J Cutan Med Surg; 2008; 12(6):282-7. PubMed ID: 19317950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
    Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
    Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.
    Di Lernia V; Ricci C; Lallas A; Ficarelli E
    J Dermatolog Treat; 2014 Feb; 25(1):73-4. PubMed ID: 23621374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.